Clinical trials
catalyst calendar across sponsors →Studies where LCTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 2 observational · 1 with posted results
Held by 8 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, Squarepoint Ops LLC, CITADEL ADVISORS LLC, +3 more) · FINRA short interest 26.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1NCT05975424observationalIncidence and severity of adverse events (AEs) | — | Active, not recruiting | Diagnostic test: Magnetic Resonance Imaging (MRI) | Spinal Cord Injuries | 25 | 2033-01-14 | in 2,340 d | 2024-08-21 |
| A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord InjuryNCT06841770Frequency and Severity of Adverse Events Related to the Delivery Device or Injection Procedure Through 30 DaysOpen-label · Treatment | Phase 1 | Recruiting | Biological: OPC1 | Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Acute, Spinal Cord Injury, Spinal Cord Injury, Chronic | 10 | 2027-08-10 | in 356 d | 2026-02-12 |
| LTFU Study of Subjects Who Received GRNOPC1NCT05919563observationalIncidence and severity of adverse events (AEs) | — | Active, not recruiting | Diagnostic test: Magnetic Resonance Imaging (MRI) | Spinal Cord Injuries | 5 | 2026-12-12 | in 115 d | 2024-08-21 |
| Dose Escalation Study of AST-OPC1 in Spinal Cord InjuryNCT02302157results2021-07-13Number of Adverse Events Within 1 Year (365 Days) That Are Related to AST-OPC1 InjectionOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: AST-OPC1 | Cervical Spinal Cord Injury, Spine Injury, Spinal Cord Trauma | 25 | Dec 2018actual | — | 2021-07-14 |
| Safety Study of GRNOPC1 in Spinal Cord InjuryNCT01217008SafetyNon-randomized · Open-label · Treatment | Phase 1 | Completed | Biological: GRNOPC1 | Spinal Cord Injury | 5 | Jul 2013actual | — | 2020-06-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19